RU2017101407A - Производные хинолина для лечения воспалительных заболеваний - Google Patents
Производные хинолина для лечения воспалительных заболеваний Download PDFInfo
- Publication number
- RU2017101407A RU2017101407A RU2017101407A RU2017101407A RU2017101407A RU 2017101407 A RU2017101407 A RU 2017101407A RU 2017101407 A RU2017101407 A RU 2017101407A RU 2017101407 A RU2017101407 A RU 2017101407A RU 2017101407 A RU2017101407 A RU 2017101407A
- Authority
- RU
- Russia
- Prior art keywords
- group
- chloro
- quinolin
- trifluoromethoxy
- amine
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims 14
- 238000011282 treatment Methods 0.000 title claims 6
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 10
- -1 N-methylpiperazinyl group Chemical group 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 108091056924 miR-124 stem-loop Proteins 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 150000003248 quinolines Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- QEMBHYSWWXWHJQ-UHFFFAOYSA-N 4,8-dichloro-N-(2-morpholin-4-ylethyl)-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound FC(F)(F)OC1=CC=C(C=C1)N(CCN1CCOCC1)C1=NC2=C(Cl)C=CC=C2C(Cl)=C1 QEMBHYSWWXWHJQ-UHFFFAOYSA-N 0.000 claims 1
- ORYIIUUHZUQAKR-UHFFFAOYSA-N 4,8-dichloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC1=CC(=NC2=C(C=CC=C12)Cl)NC1=CC=C(C=C1)OC(F)(F)F ORYIIUUHZUQAKR-UHFFFAOYSA-N 0.000 claims 1
- NQFMBBOGICEBAW-UHFFFAOYSA-N 4,8-dichloro-N-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound ClC1=CC(=NC2=C(C=CC=C12)Cl)NC1=NC=CC(=C1)C(F)(F)F NQFMBBOGICEBAW-UHFFFAOYSA-N 0.000 claims 1
- PKXAORHHDAVVQV-UHFFFAOYSA-N 4-[2-[8-chloro-2-[4-(trifluoromethoxy)phenoxy]quinolin-5-yl]oxyethyl]morpholine Chemical compound ClC=1C=CC(=C2C=CC(=NC=12)OC1=CC=C(C=C1)OC(F)(F)F)OCCN1CCOCC1 PKXAORHHDAVVQV-UHFFFAOYSA-N 0.000 claims 1
- RQSDRTCJHPMKRI-UHFFFAOYSA-N 4-[2-[8-chloro-2-[4-(trifluoromethoxy)phenoxy]quinolin-6-yl]oxyethyl]morpholine Chemical compound ClC=1C=C(C=C2C=CC(=NC=12)OC1=CC=C(C=C1)OC(F)(F)F)OCCN1CCOCC1 RQSDRTCJHPMKRI-UHFFFAOYSA-N 0.000 claims 1
- YTYFTUGTOJOWCV-UHFFFAOYSA-N 4-[2-[8-chloro-2-[4-(trifluoromethyl)pyridin-2-yl]oxyquinolin-6-yl]oxyethyl]morpholine Chemical compound ClC=1C=C(C=C2C=CC(=NC=12)OC1=NC=CC(=C1)C(F)(F)F)OCCN1CCOCC1 YTYFTUGTOJOWCV-UHFFFAOYSA-N 0.000 claims 1
- RLCYYTVUDTWGIP-UHFFFAOYSA-N 8-chloro-2-N-(2-morpholin-4-ylethyl)-4-N-(3-piperidin-1-ylpropyl)-2-N-[4-(trifluoromethoxy)phenyl]quinoline-2,4-diamine Chemical compound ClC=1C=CC=C2C(=CC(=NC=12)N(C1=CC=C(C=C1)OC(F)(F)F)CCN1CCOCC1)NCCCN1CCCCC1 RLCYYTVUDTWGIP-UHFFFAOYSA-N 0.000 claims 1
- DBYSWFJMPJHHFA-UHFFFAOYSA-N 8-chloro-2-[4-(trifluoromethoxy)phenoxy]quinoline Chemical compound FC(F)(F)OC1=CC=C(OC2=NC3=C(Cl)C=CC=C3C=C2)C=C1 DBYSWFJMPJHHFA-UHFFFAOYSA-N 0.000 claims 1
- CVWRILSKJPRHJD-UHFFFAOYSA-N 8-chloro-2-[4-(trifluoromethyl)pyridin-2-yl]oxyquinoline Chemical compound ClC=1C=CC=C2C=CC(=NC=12)OC1=NC=CC(=C1)C(F)(F)F CVWRILSKJPRHJD-UHFFFAOYSA-N 0.000 claims 1
- GKRSAXUXIUHOLY-UHFFFAOYSA-N 8-chloro-4-N-(2-morpholin-4-ylethyl)-2-N-[4-(trifluoromethyl)pyridin-2-yl]quinoline-2,4-diamine Chemical compound ClC=1C=CC=C2C(=CC(=NC=12)NC1=NC=CC(=C1)C(F)(F)F)NCCN1CCOCC1 GKRSAXUXIUHOLY-UHFFFAOYSA-N 0.000 claims 1
- MGEGYJVHRMDITM-UHFFFAOYSA-N 8-chloro-4-N-(3-piperidin-1-ylpropyl)-2-N-[4-(trifluoromethoxy)phenyl]quinoline-2,4-diamine Chemical compound ClC=1C=CC=C2C(=CC(=NC=12)NC1=CC=C(C=C1)OC(F)(F)F)NCCCN1CCCCC1 MGEGYJVHRMDITM-UHFFFAOYSA-N 0.000 claims 1
- GBNINYIPXHOKKN-UHFFFAOYSA-N 8-chloro-4-N-(3-piperidin-1-ylpropyl)-2-N-[4-(trifluoromethyl)pyridin-2-yl]quinoline-2,4-diamine Chemical compound ClC=1C=CC=C2C(=CC(=NC=12)NC1=NC=CC(=C1)C(F)(F)F)NCCCN1CCCCC1 GBNINYIPXHOKKN-UHFFFAOYSA-N 0.000 claims 1
- GDTQINGIOVWZDQ-UHFFFAOYSA-N 8-chloro-5-(2-morpholin-4-ylethoxy)-N-(2-morpholin-4-ylethyl)-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC(=C2C=CC(=NC=12)N(C1=CC=C(C=C1)OC(F)(F)F)CCN1CCOCC1)OCCN1CCOCC1 GDTQINGIOVWZDQ-UHFFFAOYSA-N 0.000 claims 1
- RBYXSIYQEOCDPC-UHFFFAOYSA-N 8-chloro-5-(2-morpholin-4-ylethoxy)-N-(3-morpholin-4-ylpropyl)-N-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound ClC=1C=CC(=C2C=CC(=NC=12)N(C1=NC=CC(=C1)C(F)(F)F)CCCN1CCOCC1)OCCN1CCOCC1 RBYXSIYQEOCDPC-UHFFFAOYSA-N 0.000 claims 1
- GHAABENZWXENIU-UHFFFAOYSA-N 8-chloro-5-(2-morpholin-4-ylethoxy)-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC(=C2C=CC(=NC=12)NC1=CC=C(C=C1)OC(F)(F)F)OCCN1CCOCC1 GHAABENZWXENIU-UHFFFAOYSA-N 0.000 claims 1
- CTAQCPMDTJKBKC-UHFFFAOYSA-N 8-chloro-5-(3-piperidin-1-ylpropoxy)-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC(=C2C=CC(=NC=12)NC1=CC=C(C=C1)OC(F)(F)F)OCCCN1CCCCC1 CTAQCPMDTJKBKC-UHFFFAOYSA-N 0.000 claims 1
- PHLMDKDCIGRNOJ-UHFFFAOYSA-N 8-chloro-5-(3-piperidin-1-ylpropoxy)-N-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound FC(F)(F)C1=CC(NC2=NC3=C(Cl)C=CC(OCCCN4CCCCC4)=C3C=C2)=NC=C1 PHLMDKDCIGRNOJ-UHFFFAOYSA-N 0.000 claims 1
- ZAVVXLZVMXBTBC-UHFFFAOYSA-N 8-chloro-6-(2-morpholin-4-ylethoxy)-N-(3-morpholin-4-ylpropyl)-N-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound ClC=1C=C(C=C2C=CC(=NC=12)N(C1=NC=CC(=C1)C(F)(F)F)CCCN1CCOCC1)OCCN1CCOCC1 ZAVVXLZVMXBTBC-UHFFFAOYSA-N 0.000 claims 1
- NRJAZXOONDIWGZ-UHFFFAOYSA-N 8-chloro-6-(2-morpholin-4-ylethoxy)-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=C(C=C2C=CC(=NC=12)NC1=CC=C(C=C1)OC(F)(F)F)OCCN1CCOCC1 NRJAZXOONDIWGZ-UHFFFAOYSA-N 0.000 claims 1
- JTYXOHRXQWZQNP-UHFFFAOYSA-N 8-chloro-6-(2-piperidin-1-ylethoxy)-N-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound FC(F)(F)C1=CC(NC2=NC3=C(Cl)C=C(OCCN4CCCCC4)C=C3C=C2)=NC=C1 JTYXOHRXQWZQNP-UHFFFAOYSA-N 0.000 claims 1
- LHPZXXLJMCDZKY-UHFFFAOYSA-N 8-chloro-6-(3-piperidin-1-ylpropoxy)-N-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound ClC=1C=C(C=C2C=CC(=NC=12)NC1=NC=CC(=C1)C(F)(F)F)OCCCN1CCCCC1 LHPZXXLJMCDZKY-UHFFFAOYSA-N 0.000 claims 1
- SQIHMNGJVWIVMN-UHFFFAOYSA-N 8-chloro-6-[2-(4-methylpiperazin-1-yl)ethoxy]-N-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound ClC=1C=C(C=C2C=CC(=NC=12)NC1=NC=CC(=C1)C(F)(F)F)OCCN1CCN(CC1)C SQIHMNGJVWIVMN-UHFFFAOYSA-N 0.000 claims 1
- MTPPNAHAHOCEOD-UHFFFAOYSA-N 8-chloro-N-(2-morpholin-4-ylethyl)-N-[2-nitro-4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)N(C1=C(C=C(C=C1)OC(F)(F)F)[N+](=O)[O-])CCN1CCOCC1 MTPPNAHAHOCEOD-UHFFFAOYSA-N 0.000 claims 1
- XLSSGMLEANKGNV-UHFFFAOYSA-N 8-chloro-N-(2-morpholin-4-ylethyl)-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)N(C1=CC=C(C=C1)OC(F)(F)F)CCN1CCOCC1 XLSSGMLEANKGNV-UHFFFAOYSA-N 0.000 claims 1
- RZZRKWMGULPKFV-UHFFFAOYSA-N 8-chloro-N-(2-pyrrolidin-1-ylethyl)-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)N(C1=CC=C(C=C1)OC(F)(F)F)CCN1CCCC1 RZZRKWMGULPKFV-UHFFFAOYSA-N 0.000 claims 1
- UXWXCEPNJDTEDD-UHFFFAOYSA-N 8-chloro-N-(3-morpholin-4-ylpropyl)-N-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)N(C1=NC=CC(=C1)C(F)(F)F)CCCN1CCOCC1 UXWXCEPNJDTEDD-UHFFFAOYSA-N 0.000 claims 1
- IFNBIAFKDRMVAU-UHFFFAOYSA-N 8-chloro-N-(3-piperidin-1-ylpropyl)-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)N(C1=CC=C(C=C1)OC(F)(F)F)CCCN1CCCCC1 IFNBIAFKDRMVAU-UHFFFAOYSA-N 0.000 claims 1
- WSYNAXHDNOZXGA-UHFFFAOYSA-N 8-chloro-N-(4-morpholin-4-ylbutyl)-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)N(C1=CC=C(C=C1)OC(F)(F)F)CCCCN1CCOCC1 WSYNAXHDNOZXGA-UHFFFAOYSA-N 0.000 claims 1
- ANYGTKVWWHXTBT-UHFFFAOYSA-N 8-chloro-N-[3-fluoro-4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)NC1=NC=CC(=C1F)C(F)(F)F ANYGTKVWWHXTBT-UHFFFAOYSA-N 0.000 claims 1
- PQGXDRHWPVFSAD-UHFFFAOYSA-N 8-chloro-N-methyl-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound CN(C1=CC=C(OC(F)(F)F)C=C1)C1=NC2=C(Cl)C=CC=C2C=C1 PQGXDRHWPVFSAD-UHFFFAOYSA-N 0.000 claims 1
- DYGHCCIWSOEVRG-UHFFFAOYSA-N 8-chloro-N-methyl-N-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound ClC=1C=CC=C2C=CC(=NC=12)N(C1=NC=CC(=C1)C(F)(F)F)C DYGHCCIWSOEVRG-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- YFZRCKOIZVPOJY-UHFFFAOYSA-N ClC=1C=CC(=C2C=CC(=NC=12)C1(C(C=C(C=C1)OC(F)(F)F)N)N)OCCN1CCOCC1 Chemical compound ClC=1C=CC(=C2C=CC(=NC=12)C1(C(C=C(C=C1)OC(F)(F)F)N)N)OCCN1CCOCC1 YFZRCKOIZVPOJY-UHFFFAOYSA-N 0.000 claims 1
- CIRAJFLUJGDIJC-UHFFFAOYSA-N N-[5-bromo-4-(trifluoromethyl)pyridin-2-yl]-8-chloroquinolin-2-amine Chemical compound BrC=1C(=CC(=NC=1)NC1=NC2=C(C=CC=C2C=C1)Cl)C(F)(F)F CIRAJFLUJGDIJC-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- AOCNMCNJVKDWPB-UHFFFAOYSA-N [2-[(8-chloroquinolin-2-yl)amino]-5-(trifluoromethoxy)phenyl] dihydrogen phosphate Chemical compound OP(O)(=O)OC1=C(NC2=NC3=C(Cl)C=CC=C3C=C2)C=CC(OC(F)(F)F)=C1 AOCNMCNJVKDWPB-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
Claims (88)
1. Соединение формулы (I)
где Z представляет собой С или N,
V представляет собой С или N,
R независимо представляет собой атом водорода, атом галогена или группу, выбранную из группы -CN, гидроксильной группы, (С1-С3)фторалкильной группы, группы (С1-С3)фторалкокси, (С3-С6)циклоалкильной группы, группы -NO2, группы -NR1R2, группы (С1-С4)алкокси, группы фенокси, группы -NR1-SO2-NR1R2, группы -NR1-SO2-R1, группы -NR1-C(=O)-R1, группы -NR1-C(=O)-NR1R2, группы -SO2-NR1R2, группы -SO3H, группы -O-SO2-OR3, группы -O-P(=O)-(OR3)(OR4), группы -O-CH2-COOR3 и (С1-С3)алкильной группы, где указанный алкил необязательно монозамещен гидроксильной группой,
Q представляет собой N или О при условии, что R'' отсутствует, когда Q представляет собой О,
R1 и R2 независимо представляют собой атом водорода или (С1-С3)алкильную группу,
R3 и R4 независимо представляют собой атом водорода, Li+, Na+, K+, N+(Ra)4 или бензильную группу,
n равно 1, 2 или 3,
n' равно 1, 2 или 3,
R' независимо представляет собой атом водорода или группу, выбранную из (С1-С3)алкильной группы, атома галогена, группы -NO2, группы -NR1R2, группы морфолинил или морфолино, N-метилпиперазинильной группы, (С1-С3)фторалкильной группы, группы -O-P(=O)-(OR3)(OR4) и группы -CN, и может дополнительно представлять собой группу, выбранную из:
где
А представляет собой ковалентную связь, атом кислорода или NH,
В представляет собой ковалентную связь или NH,
m равно 1, 2, 3, 4 или 5,
р равно 1, 2 или 3,
Ra и Rb независимо представляют собой атом водорода, (С1-С5)алкильную группу или (С3-С6)циклоалкильную группу,
Ra и Rb дополнительно могут образовать вместе с атомом азота, к которому они присоединены, насыщенный 5- или 6-членный гетероцикл, необязательно содержащий дополнительный гетероатом, выбранный из N, О и S, где указанный гетероцикл необязательно замещен одним или более Ra при условии, что, когда R' представляет собой группу (IIa) или (IIIa), n' может быть равно 2 или 3 только в том случае, если другие группы R' отличаются от указанной группы (IIa) или (IIIa),
R'' представляет собой атом водорода, (С1-С4)алкильную группу или группу (IIa), как определено выше,
или любая из его фармацевтически приемлемых солей,
для применения при лечении и/или профилактике воспалительного заболевания.
3. Соединение по п. 1 или п. 2, где R независимо представляет собой атом водорода, метильную группу, группу метокси, трифторметильную группу, группу трифторметокси, аминогруппу, атом галогена и группу -O-P(=O)-(OR3)(OR4), и более конкретно атом фтора или хлора, группу трифторметокси и аминогруппу.
4. Соединение по любому из пп. 1-3, где R' независимо представляет собой атом водорода, атом галогена и более конкретно атома фтора или хлора, аминогруппу, метильную группу, группу -O-P(=O)-(OR3)(OR4) или группу , где А представляет собой О или NH, m равно 2 или 3, и X1 представляет собой О, СН2 или N-CH3, при условии, что, когда R' представляет собой такую группу, n' равно 1 или 2, и, когда n' равно 2, другая группа R' отличается от указанной группы, или альтернативно R' независимо представляет собой атом водорода, атом галогена, и более конкретно атом фтора или хлора, метильную группу или группу , где А представляет собой О или NH, m равно 2, и X1 представляет собой О, СН2 или N-СН3, при условии, что, когда R' представляет собой такую группу, n' равно 1 или 2, и, когда n' равно 2, другая группа R' отличается от указанной группы.
5. Соединение по любому из пп. 1-4, где Q представляет собой N.
6. Соединение по любому из пп. 1-5, выбранное из
где R, R', R'', n и n' являются такими, как определено в любом из пп. 1-4.
7. Соединение формулы (Id) или (Ie):
где R, R', n и n' являются такими, как определено в любом из пп. 1-4.
8. Соединение, выбранное из перечня, состоящего из:
(8) 8-хлор-5-(3-(пиперидин-1-ил)пропокси)-N-(4-(трифторметил)пиридин-2-ил)хинолин-2-амина;
(9) 8-хлор-N4-(3-(пиперидин-1-ил)пропил)-N2-(4-(трифторметил)пиридин-2-ил)хинолин-2,4-диамина;
(10) 8-хлор-N-метил-N-(4-(трифторметил)пиридин-2-ил)хинолин-2-амина;
(11) 8-хлор-N4-(2-морфолиноэтил)-N2-(4-(трифторметил)пиридин-2-ил)хинолин-2,4-диамина;
(13) 4,8-дихлор-N-(4-(трифторметил)пиридин-2-ил)хинолин-2-амина;
(14) 8-хлор-N-(3-морфолинопропил)-N-(4-(трифторметил)пиридин-2-ил)хинолин-2-амина;
(15) 8-хлор-6-(2-морфолиноэтокси)-N-(3-морфолинопропил)-N-(4-(трифторметил)пиридин-2-ил)хинолин-2-амина;
(16) 8-хлор-5-(2-морфолиноэтокси)-N-(3-морфолинопропил)-N-(4-(трифторметил)пиридин-2-ил)хинолин-2-амина;
(17) 8-хлор-6-(2-(4-метилпиперазин-1-ил)этокси)-N-(4-(трифторметил)пиридин-2-ил)хинолин-2-амина;
(18) 8-хлор-6-(2-(пиперидин-1-ил)этокси)-N-(4-(трифторметил)пиридин-2-ил)хинолин-2-амина;
(19) 8-хлор-6-(3-(пиперидин-1-ил)пропокси)-N-(4-(трифторметил)пиридин-2-ил)хинолин-2-амина;
(20) 8-хлор-N-(3-фтор-4-(трифторметил)пиридин-2-ил)хинолин-2-амина;
(21) N-(5-бром-4-(трифторметил)пиридин-2-ил)-8-хлорхинолин-2-амина;
(22) N2-(8-хлорхинолин-2-ил)-N5-(3-(4-метилпиперазин-1-ил)пропил)-4-(трифторметил)пиридин-2,5-диамина;
(28) 8-хлор-N-метил-N-(4-(трифторметокси)фенил)хинолин-2-амина;
(29) 8-хлор-5-(3-(пиперидин-1-ил)пропокси)-N-(4-(трифторметокси)фенил)хинолин-2-амина;
(30) 8-хлор-N-(3-(пиперидин-1-ил)пропил)-N-(4-(трифторметокси)фенил)хинолин-2-амина;
(31) 8-хлор-N-(2-морфолиноэтил)-N-(4-(трифторметокси)фенил)хинолин-2-амина;
(32) 8-хлор-N-(2-(пирролидин-1-ил)этил)-N-(4-(трифторметокси)фенил)хинолин-2-амина;
- (33) 8-хлор-N-(4-морфолинобутил)-N-(4-(трифторметокси)фенил)хинолин-2-амина;
- (34) 8-хлор-N4-(3-(пиперидин-1-ил)пропил)-N2-(4-(трифторметокси)фенил)хинолин-2,4-диамина;
(35) 4,8-дихлор-N-(4-(трифторметокси)фенил)хинолин-2-амина;
(36) 8-хлор-5-(2-морфолиноэтокси)-N-(4-(трифторметокси)фенил)хинолин-2-амина;
(37) N1-(4,8-дихлорхинолин-2-ил)-4-(трифторметокси)бензол-1,2-диамина;
(38) 4,8-дихлор-N-(2-морфолиноэтил)-N-(4-(трифторметокси)фенил)хинолин-2-амина;
(39) 8-хлор-6-(2-морфолиноэтокси)-N-(4-(трифторметокси)фенил)хинолин-2-амина;
(40) 8-хлор-N2-(2-морфолиноэтил)-N4-(3-(пиперидин-1-ил)пропил)-N2-(4-(трифторметокси)фенил)хинолин-2,4-диамина;
(41) 8-хлор-N-(2-морфолиноэтил)-N-(2-нитро-4-(трифторметокси)фенил)хинолин-2-амина;
(42) N1(8-хлорхинолин-2-ил)-N1-(2-морфолиноэтил)-4-(трифторметокси)бензол-1,2-диамина;
(43) 8-хлор-5-(2-морфолиноэтокси)-N-(2-морфолиноэтил)-N-(4-(трифторметокси)фенил)хинолин-2-амина;
(44) N1-(8-хлор-5-(2-морфолиноэтокси)хинолин-2-ил)-4-(трифторметокси)бензол-1,2-диамина;
(46) 8-хлор-2-((4-(трифторметил)пиридин-2-ил)окси)хинолина;
(47) 4-(2-((8-хлор-2-((4-(трифторметил)пиридин-2-ил)окси)хинолин-6-ил)окси)этил)морфолина;
(48) 8-хлор-2-(4-(трифторметокси)фенокси)хинолина;
(49) 4-(2-((8-хлор-2-(4-(трифторметокси)фенокси)хинолин-6-ил)окси)этил)морфолина;
(50) 4-(2-((8-хлор-2-(4-(трифторметокси)фенокси)хинолин-5-ил)окси)этил)морфолина;
(51) моно-[8-хлор-2-(4-трифторметил-пиридин-2-иламино)-хинолин-6-ил]ового эфира фосфорной кислоты;
(52) моно-[2-(8-хлор-хинолин-2-иламино)-5-трифторметокси-фенил]ового эфира фосфорной кислоты;
(53) моно-[8-хлор-2-(4-трифторметокси-фениламино)-хинолин-6-ил]ового эфира фосфорной кислоты
и их фармацевтически приемлемых солей, и более конкретно выбранное из соединений (8), (9), (10), (11), (30), (46), (47), (48), (49) и (50), как определено выше, или одной из их фармацевтически приемлемых солей.
9. Соединение по любому из пп. 1-8 для применения при лечении, уменьшении вероятности развития или отсрочки возникновения указанного воспалительного заболевания.
10. Соединение по любому из пп. 1-8, где указанное воспалительное заболевание выбрано из перечня, состоящего из: воспалительного заболевания, обусловленного аутоиммунным заболеванием, воспалительного заболевания центральной нервной системы (ЦНС), воспалительного заболевания суставов, воспалительного заболевания пищеварительного тракта, воспалительного заболевания кожи и других воспалительных заболеваний, связанных с эпителиальными клетками, воспаления, обусловленного раком, воспаления, обусловленного раздражением, и воспаления, обусловленного повреждением.
11. Соединение по любому из пп. 1-8, где указанное воспалительное заболевание выбрано из перечня, состоящего из: воспалительного заболевания кишечника, ревматоидного артрита, болезни Крона, язвенного колита, рассеянного склероза, болезни Альцгеймера, болезни Паркинсона, остеоартрита, атеросклероза, анкилозирующего спондилита, псориаза, дерматита, синдрома Шегрена, бронхита, бронхиальной астмы и воспаления, обусловленного карциномой толстой кишки, и, в частности, воспалительного заболевания кишечника, ревматоидного артрита, болезни Крона, язвенного колита, рассеянного склероза, остеоартрита, анкилозирующего спондилита, псориаза, синдрома Шегрена, бронхита и воспаления, обусловленного карциномой толстой кишки.
12. Фармацевтическая композиция, содержащая по меньшей мере одно соединение по п. 10 или выбранное из соединений (8), (9), (10), (11), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (28), (29), (30), (31), (32), (33), (34), (35), (36), (37), (38), (39), (40), (41), (42), (43), (44), (46), (47), (48), (49), (50), (51), (52) и (53), и более конкретно одного из соединений (8), (9), (10), (11), (30), (46), (47), (48), (49) и (50), как определено в п. 8.
13. Применение по меньшей мере одной миРНК in vitro или ex vivo, где указанная по меньшей мере одна миРНК представляет собой miR-124, в качестве биомаркера для скрининга производного хинолина и в частности, соединения формулы (I) по п. 1, предположительно эффективного при лечении и/или профилактике воспалительного заболевания.
14. Способ скрининга in vitro или ex vivo производного хинолина и, в частности, соединения формулы (I) по любому из пп. 1-6, предположительно эффективного при лечении и/или профилактике воспалительного заболевания, включающий по меньшей мере стадию, на которой:
а) обеспечивают эукариотическую клетку,
b) приводят указанную клетку в контакт с производным хинолина и, в частности, с соединением формулы (I).
c) определяют экспрессию miR-124 в указанной клетке, и
d) выбирают соединение-кандидат, предположительно эффективное при лечении и/или профилактике воспалительного заболевания, когда уровень экспрессии miR-124, определенный на стадии с), повышен относительно эталонного значения.
15. Способ по п. 14, где указанная эукариотическая клетка представляет собой мононуклеарную клетку периферической крови (МКПК).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14306164.6 | 2014-07-17 | ||
EP14306164.6A EP2974729A1 (en) | 2014-07-17 | 2014-07-17 | Quinoline derivatives for use in the treatment of inflammatory diseases |
PCT/EP2015/066458 WO2016009065A2 (en) | 2014-07-17 | 2015-07-17 | Quinoline derivatives for the treatment of inflammatory diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2021134325A Division RU2021134325A (ru) | 2014-07-17 | 2015-07-17 | Производные хинолина для лечения воспалительных заболеваний |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017101407A true RU2017101407A (ru) | 2018-08-17 |
RU2017101407A3 RU2017101407A3 (ru) | 2019-01-17 |
RU2760686C2 RU2760686C2 (ru) | 2021-11-29 |
Family
ID=51220531
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017101407A RU2760686C2 (ru) | 2014-07-17 | 2015-07-17 | Производные хинолина для лечения воспалительных заболеваний |
RU2021134325A RU2021134325A (ru) | 2014-07-17 | 2015-07-17 | Производные хинолина для лечения воспалительных заболеваний |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2021134325A RU2021134325A (ru) | 2014-07-17 | 2015-07-17 | Производные хинолина для лечения воспалительных заболеваний |
Country Status (20)
Country | Link |
---|---|
US (5) | US10435370B2 (ru) |
EP (3) | EP2974729A1 (ru) |
JP (3) | JP6884690B2 (ru) |
KR (2) | KR20230078827A (ru) |
CN (5) | CN117205212A (ru) |
AU (4) | AU2015289033A1 (ru) |
CA (2) | CA3166018A1 (ru) |
CU (2) | CU24565B1 (ru) |
DK (1) | DK3169328T3 (ru) |
ES (1) | ES2914066T3 (ru) |
HR (1) | HRP20220598T1 (ru) |
HU (1) | HUE058713T2 (ru) |
LT (1) | LT3169328T (ru) |
MX (2) | MX2017000533A (ru) |
PL (1) | PL3169328T3 (ru) |
PT (1) | PT3169328T (ru) |
RS (1) | RS63231B1 (ru) |
RU (2) | RU2760686C2 (ru) |
SI (1) | SI3169328T1 (ru) |
WO (1) | WO2016009065A2 (ru) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
EP3059591A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
EP3058940A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
EP3669874A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
KR102399037B1 (ko) * | 2020-01-06 | 2022-05-17 | 성균관대학교산학협력단 | 아민화된 아진의 신규한 제조방법 |
CN114073700B (zh) * | 2020-08-19 | 2023-08-01 | 中山大学中山眼科中心 | Iox1在自身免疫性疾病的预防和/或治疗中的应用 |
CN117222639A (zh) * | 2021-05-27 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | 喹啉胺类化合物、其制备方法及其在医药上的应用 |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
WO2023138657A1 (zh) * | 2022-01-24 | 2023-07-27 | 江苏恒瑞医药股份有限公司 | 喹啉胺类化合物、其制备方法及其在医药上的应用 |
EP4215196A1 (en) * | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB585362A (en) | 1944-08-31 | 1947-02-05 | Francis Henry Swinden Curd | New heterocyclic compounds |
BE486034A (ru) | 1947-11-28 | |||
DE958647C (de) | 1952-12-28 | 1957-02-21 | Hoechst Ag | Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen |
JPS5272821A (en) | 1975-12-15 | 1977-06-17 | Mitsubishi Petrochem Co Ltd | Herbicide |
FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
JPS5651454A (en) * | 1979-10-01 | 1981-05-09 | Nissan Chem Ind Ltd | Hydroquinone derivative and its preparation |
US4738710A (en) | 1979-11-19 | 1988-04-19 | Ici Australia Limited | Herbicidal alkane carboxylic acid derivatives |
US4425343A (en) | 1980-10-24 | 1984-01-10 | Nissan Chemical Industries, Ltd. | Benzoazine ether or thioether linkage containing urea compounds, process for producing same and insecticides containing said compounds |
JPS5772968A (en) | 1980-10-24 | 1982-05-07 | Nissan Chem Ind Ltd | Aniline derivative and its preparation |
FR2627493B1 (fr) | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
DE60008509T2 (de) | 1999-04-05 | 2004-12-16 | City Of Hope, Duarte | Neue Hemmer von fortgeschrittenen Glykosilierungsendprodukten (AGEs) |
UA75055C2 (ru) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Производные бензоимидазола, которые применяются как антипролиферативное средство, фармацевтическая композиция на их основании |
DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
KR100856622B1 (ko) | 2001-01-22 | 2008-09-03 | 메모리 파마슈티칼스 코포레이션 | 포스포디에스테라제 4 억제제 |
GB0109103D0 (en) | 2001-04-11 | 2001-05-30 | Pfizer Ltd | Novel compounds |
WO2003000660A1 (en) | 2001-06-22 | 2003-01-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same |
US6498254B1 (en) | 2001-10-29 | 2002-12-24 | Uniroyal Chemical Company, Inc. | Antiretroviral compounds and compositions |
WO2003099284A1 (en) | 2002-05-22 | 2003-12-04 | Amgen Inc. | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
JP2006504656A (ja) | 2002-07-19 | 2006-02-09 | メモリー・ファーマシューティカルズ・コーポレイション | N−置換されたアニリン及びジフェニルアミンアナログを含むホスホジエステラーゼ4インヒビター |
WO2006081444A2 (en) | 2005-01-28 | 2006-08-03 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
WO2004078731A1 (fr) | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee |
WO2004080463A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
CA2542329A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
EP1678185B1 (en) * | 2003-10-31 | 2008-10-08 | Otsuka Pharmaceutical Co., Ltd. | 2,3-dihydro-6-nitroimidazo [2,1-b] oxazole compounds for the treatment of tuberculosis |
ES2369835T3 (es) | 2003-11-19 | 2011-12-07 | Array Biopharma, Inc. | Inhibidores bicíclicos de mek y métodos de síntesis de los mismos. |
CA2551508C (en) * | 2003-12-23 | 2011-08-09 | Pfizer Inc. | Novel quinoline derivatives |
WO2005112930A1 (en) | 2004-05-21 | 2005-12-01 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and anti-hiv agents |
WO2006051311A1 (en) | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
AU2005312048B2 (en) | 2004-11-30 | 2012-08-02 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
EP1863522A4 (en) | 2005-03-18 | 2010-11-10 | Univ California | CORRECTIVE TO THE PROCESSING OF MUTANT CFTR IMPACT COMPOUNDS AND ITS APPLICATIONS |
WO2007000876A1 (ja) | 2005-06-29 | 2007-01-04 | Adeka Corporation | 樹脂添加剤組成物及びその樹脂組成物 |
AU2006300864A1 (en) | 2005-10-10 | 2007-04-19 | Council Of Scientific And Industrial Research | Human microrna targets in HIV genome and a method of identification thereof |
WO2007103162A2 (en) * | 2006-03-01 | 2007-09-13 | Samaritan Pharmaceuticals, Inc. | Structure based drug design of steroidogenesis inhibitors |
DK2044026T3 (da) | 2006-06-22 | 2014-06-30 | Prana Biotechnology Ltd | Fremgangsmde til behandling af cerebral glioma tumor |
FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
US8030487B2 (en) | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
JP5331953B2 (ja) | 2006-09-21 | 2013-10-30 | ピラマル エンタープライジーズ リミテッド | 代謝性障害の治療のための3−アミノ−ピリジン誘導体 |
EP2121620B1 (en) | 2007-01-19 | 2015-06-17 | Ardea Biosciences, Inc. | Inhibitors of mek |
FR2912745A1 (fr) | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
US20100249184A1 (en) | 2007-03-16 | 2010-09-30 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
NZ579834A (en) | 2007-03-23 | 2012-03-30 | Amgen Inc | Heterocyclic compounds as selective inhibitors of PI3K activity |
DE112008001206B4 (de) | 2007-05-17 | 2019-01-31 | Lg Chem. Ltd. | Neue Anthrazen-Derivate und organische elektronische Vorrichtung, die diese verwendet |
WO2008153692A2 (en) | 2007-05-22 | 2008-12-18 | The Brigham And Women's Hospital, Inc. | Microrna expression profiling of cerebrospinal fluid |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
CN101801194A (zh) | 2007-08-15 | 2010-08-11 | 记忆医药公司 | 具有5-ht6受体亲和力的3’取代的化合物 |
WO2009029617A1 (en) | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
EP2235213A2 (en) | 2007-12-20 | 2010-10-06 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
KR100974562B1 (ko) | 2007-12-31 | 2010-08-06 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자 |
FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
JP2009174368A (ja) | 2008-01-23 | 2009-08-06 | Toyota Motor Corp | 内燃機関の排気浄化装置 |
CN102015650A (zh) * | 2008-03-07 | 2011-04-13 | 弗·哈夫曼-拉罗切有限公司 | 作为5-ht5a受体拮抗剂的2-氨基喹啉衍生物 |
EP2271931A4 (en) | 2008-04-25 | 2011-10-12 | Merck Sharp & Dohme | MICRO-RNA BIOMARKERS FOR TISSUE INJURIES |
US20160041153A1 (en) | 2008-11-12 | 2016-02-11 | Kirk Brown | Biomarker compositions and markers |
WO2010107965A1 (en) | 2009-03-19 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Process for preparing sulfonyl quinolines |
WO2010127208A1 (en) * | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
US8633320B2 (en) | 2009-05-05 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Process for preparing bromo-substituted quinolines |
CN102459272B (zh) | 2009-05-27 | 2014-08-06 | 健泰科生物技术公司 | 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法 |
MX2019008390A (es) | 2009-06-12 | 2019-09-09 | Abivax | Compuestos utiles para tratar cancer. |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
DK2440545T3 (da) * | 2009-06-12 | 2019-07-22 | Abivax | Forbindelser, der er anvendelige til behandling af cancer |
EP2266972A1 (en) | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
US8962583B2 (en) * | 2009-06-25 | 2015-02-24 | The Brigham And Women's Hospital, Inc. | Treatment of inflammatory diseases using miR-124 |
US8933033B2 (en) * | 2009-10-09 | 2015-01-13 | Cbio Limited | Chaperonin 10 variants |
ES2597554T3 (es) | 2009-11-04 | 2017-01-19 | Diamir, Llc | Métodos de utilización de micro-ARN de fluidos corporales para el diagnóstico y control del deterioro cognitivo leve |
CA2803056C (en) * | 2010-06-23 | 2017-05-16 | Hanmi Science Co., Ltd. | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
US20140051085A1 (en) | 2011-03-01 | 2014-02-20 | The Scripps Research Institute | Direct reprogramming of human fibroblasts to functional neurons under defined conditions |
WO2013039394A1 (en) | 2011-09-15 | 2013-03-21 | Self-Screen B.V. | Methylation analysis on self-samples as triage tool for hpv-positive women |
CA2887066A1 (en) | 2012-10-04 | 2014-04-10 | Oyagen, Inc. | Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |
EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
JP6895251B2 (ja) * | 2013-07-05 | 2021-06-30 | アビバックス | レトロウイルスにより引き起こされる疾患を処理する為に有用な化合物 |
EP3110415A4 (en) * | 2014-02-28 | 2017-12-13 | The Texas A & M University System | Compositions and methods for inhibition of mycobacteria |
EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
EP2974729A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
EP3058940A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
PT3429998T (pt) | 2016-03-18 | 2021-11-04 | Prosynergia S A R L | Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais |
EP3669873A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
-
2014
- 2014-07-17 EP EP14306164.6A patent/EP2974729A1/en not_active Ceased
-
2015
- 2015-07-17 PT PT157389164T patent/PT3169328T/pt unknown
- 2015-07-17 WO PCT/EP2015/066458 patent/WO2016009065A2/en active Application Filing
- 2015-07-17 CN CN202311170460.4A patent/CN117205212A/zh active Pending
- 2015-07-17 JP JP2017502214A patent/JP6884690B2/ja active Active
- 2015-07-17 CN CN202311055802.8A patent/CN117281805A/zh active Pending
- 2015-07-17 DK DK15738916.4T patent/DK3169328T3/da active
- 2015-07-17 CN CN202311055153.1A patent/CN117379426A/zh active Pending
- 2015-07-17 SI SI201531837T patent/SI3169328T1/sl unknown
- 2015-07-17 KR KR1020237017415A patent/KR20230078827A/ko not_active Application Discontinuation
- 2015-07-17 KR KR1020177003729A patent/KR102537958B1/ko active IP Right Grant
- 2015-07-17 ES ES15738916T patent/ES2914066T3/es active Active
- 2015-07-17 CU CU2019000043A patent/CU24565B1/es unknown
- 2015-07-17 LT LTEPPCT/EP2015/066458T patent/LT3169328T/lt unknown
- 2015-07-17 CA CA3166018A patent/CA3166018A1/en active Pending
- 2015-07-17 AU AU2015289033A patent/AU2015289033A1/en not_active Abandoned
- 2015-07-17 RU RU2017101407A patent/RU2760686C2/ru active
- 2015-07-17 CN CN202311056068.7A patent/CN117568459A/zh active Pending
- 2015-07-17 CN CN201580046384.3A patent/CN107207463B/zh active Active
- 2015-07-17 EP EP15738916.4A patent/EP3169328B1/en active Active
- 2015-07-17 HR HRP20220598TT patent/HRP20220598T1/hr unknown
- 2015-07-17 RS RS20220479A patent/RS63231B1/sr unknown
- 2015-07-17 RU RU2021134325A patent/RU2021134325A/ru unknown
- 2015-07-17 CU CU2017000004A patent/CU24459B1/es unknown
- 2015-07-17 HU HUE15738916A patent/HUE058713T2/hu unknown
- 2015-07-17 EP EP21211115.7A patent/EP3998070A1/en active Pending
- 2015-07-17 MX MX2017000533A patent/MX2017000533A/es unknown
- 2015-07-17 CA CA2954951A patent/CA2954951C/en active Active
- 2015-07-17 PL PL15738916T patent/PL3169328T3/pl unknown
- 2015-07-17 US US15/326,755 patent/US10435370B2/en active Active
-
2017
- 2017-01-12 MX MX2021006754A patent/MX2021006754A/es unknown
-
2019
- 2019-08-29 US US16/554,748 patent/US10981874B2/en active Active
-
2020
- 2020-01-17 AU AU2020200333A patent/AU2020200333B2/en active Active
- 2020-08-17 US US16/994,954 patent/US11649210B2/en active Active
- 2020-09-15 JP JP2020154962A patent/JP7208957B2/ja active Active
- 2020-12-07 US US17/113,369 patent/US11649211B2/en active Active
-
2021
- 2021-03-30 AU AU2021201960A patent/AU2021201960B2/en active Active
-
2022
- 2022-05-17 US US17/746,410 patent/US20220315535A1/en active Pending
-
2023
- 2023-01-06 JP JP2023001382A patent/JP2023052265A/ja active Pending
- 2023-04-19 AU AU2023202386A patent/AU2023202386A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017101407A (ru) | Производные хинолина для лечения воспалительных заболеваний | |
US10807982B2 (en) | Bromodomain inhibitors | |
US11498913B2 (en) | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
ES2940885T3 (es) | Compuestos útiles para tratar el envejecimiento prematuro y en particular la progeria | |
JP6570776B2 (ja) | 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物 | |
ZA200409639B (en) | Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles | |
KR101257158B1 (ko) | 단백질 티로신 키나제 억제제로서의 퀴놀린 및 퀴녹살린의 유도체 | |
Lam et al. | Preparation of 8-hydroxyquinoline derivatives as potential antibiotics against Staphylococcus aureus | |
BG108325A (bg) | Нови 4-анилинохинолин-3-карбоксамиди | |
KR101893627B1 (ko) | 티아졸 유도체 | |
WO2013003586A1 (en) | Quinazolines as therapeutic compounds and related methods of use | |
WO2012016082A1 (en) | Quinoline derivatives and melk inhibitors containing the same | |
US8883763B2 (en) | Use of isoquinolones for preparing drugs, novel isoquinolones and method for synthesising same | |
JP2016525076A5 (ru) | ||
AU2015317327A1 (en) | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
JP6378802B2 (ja) | 早期老化、特には早老症を治療する為に有用な化合物 | |
CZ303899B6 (cs) | Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem | |
JP2021510729A (ja) | 受容体チロシンキナーゼのtyro3、axlおよびmertk(tam)ファミリー阻害剤としてのヘテロ環化合物 | |
JP4858683B2 (ja) | キノロン誘導体又はその塩の製造法 | |
KR101127725B1 (ko) | 아미드 유도체 |